Brii Biosciences Limited

As of December 31, 2025, Brii Biosciences Limited carries a market capitalization of 1.02B, placing it among publicly traded companies globally. Its enterprise value stands at -1.19B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Brii Biosciences Limited's next confirmed earnings release is scheduled for March 19, 2027.

As of December 31, 2025, Brii Biosciences Limited has 721.18M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Brii Biosciences Limited maintains a current ratio of 60.73, meaning it holds 60.7x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, Brii Biosciences Limited's stock has declined approximately 53.48% over the past 52 weeks. The 50-day moving average sits at 0.91, while the 200-day moving average is 1.20.

As of December 31, 2025, Brii Biosciences Limited holds 2.16B in cash and equivalents against 9.94M in total debt, resulting in a net debt position of -675.35M. Total book value stands at 2.64B, with working capital of 2.15B providing operational flexibility.